What does the acceptance of Novo Nordisk's application for oral Wegovy by China's drug regulator signify in the context of the GLP-1 weight-loss drug race in China?

The acceptance signifies that Novo Nordisk has formally entered the regulatory review process for its oral GLP-1 weight-loss drug Wegovy in China, aiming to compete with Eli Lilly — which submitted its application for oral orforglipron earlier and could launch in China as soon as this year. This move reflects Novo Nordisk’s strategic effort to catch up in the world’s second-largest pharmaceutical market, where multiple companies including Pfizer and Innovent Biologics are also vying for share with once-weekly GLP-1 injections, amid rising obesity concerns projected to affect over 65% of China’s population by 2030.

Why are Novo Nordisk and Eli Lilly prioritizing oral formulations of GLP-1 drugs like Wegovy and orforglipron in China?

Novo Nordisk and Eli Lilly believe oral weight-loss pills could attract patients who are reluctant to use injectable therapies, broadening accessibility and adoption in China’s large and growing overweight/obese population. Both companies have already secured early approvals for their oral GLP-1 drugs in the U.S. and Britain — Novo launched its Wegovy pill in the U.S. this year, while Lilly gained U.S. approval for orforglipron in April — underscoring the global strategic importance of oral delivery as a patient-friendly alternative to weekly injections.

China's drug regulator accepts Novo Nordisk's application for oral Wegovy

Aug 26, 2026

Novo Nordisk confirmed China's drug regulator accepted its application for an oral version of Wegovy, joining competitors like Eli Lilly in the expanding Chinese weight-loss market. Analysts project GLP-1 therapy sales could reach $4.46 billion within five to seven years.

reuters

2026-07-22

Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads

2026-08-26

China's drug regulator accepts Novo Nordisk's application for oral Wegovy

China's drug regulator accepts Novo Nordisk's application for oral Wegovy

FAQ